AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05521178 — intervention group
Intervention type: DEVICE
Intervention: Mobile cardiac telemetry
Description: Mobile cardiac telemetry at baseline and 6 months
Study NCT05521178 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure monitoring
Description: Home blood pressure monitoring three times per week
Study NCT05521178 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Blood draw at baseline, 3 and 6 months
Study NCT05494619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight ≥ 40 kilograms (kg) and \<100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Day 1, followed by crovalimab 340 mg SC injections on Days 2, 8, 15 and 22 in all participants.
Study NCT05494619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered IV on Day 1 at a dose of 1000 mg for participants with body weight ≥ 40 kg to \< 100 kg, or 1500 mg for participants with body weight ≥ 100 kg. It will be administered SC on Days 2, 8, 15, and 22 at a dose 340 mg in all participants.
Study NCT05494619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin therapy
Description: All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.
Study NCT05494619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous immunoglobulin therapy
Description: All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.
Study NCT05538208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: MMF dosed 600mg/m2 body surface area per dose about every 12 hours
Study NCT05538208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: MMF dosed twice daily to achieve an area under the concentration-time curve (AUC 0-12h) of MPA >=60-70 mg\*h/L
Study NCT06515522 — intervention group
Intervention type: OTHER
Intervention: differential diagnosis
Description: this is a retrospective observational study. no intervention has been or will be performed
Study NCT06010732 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0 ppm F (placebo, negative control)
Description: • Each subject will use this product during one of the three treatment periods in the crossover study design.
Study NCT06010732 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm F as sodium fluoride (positive control)
Description: • Each subject will use this product during one of the three treatment periods in the crossover study design.
Study NCT06010732 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm F as sodium fluoride Test Product
Description: • Each subject will use this product during one of the three treatment periods in the crossover study design.
Study NCT06202417 — intervention group
Intervention type: DRUG
Intervention: Fruquintinib
Description: an oral tyrosine kinase inhibitor (TKI)
Study NCT06634862 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normatec Air Compression
Description: Intermittent pneumatic pressure has been used in other studies, usually for deep vein thrombosis and vascular disorders. In this way, it has not been compared with other recovery interventions for post-exercise recovery applications.
Study NCT06054828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHELP@ICU
Description: The 14-day mHELP@ICU consists of the following three components:~1. Cognitive engagement twice daily: Participants will receive orienting communication, plus one of the following training on attention, memory, or function execution.~2. Physical activity once daily: Participants will receive a passive range of motion(ROM) and/or anti-gravity ROM exercise if tolerated.~3. Feeding monitor daily: The exact feeding data will be abstracted from medical records.
Study NCT05801042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Placebo product
Study NCT05801042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Encapsulated Lactocaseibacillus rhamnosus
Description: Probiotic product
Study NCT05801042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-encapsulated Lactocaseibacillus rhamnosus
Description: Probiotic product
Study NCT05211284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 4 mg
Description: Subjects randomized to Saroglitazar Magnesium 4 mg arm will receive Saroglitazar Magnesium 4 mg treatment until the duration of study (24 weeks).
Study NCT05211284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to Placebo arm will receive Placebo treatment until the duration of study (24 weeks).
Study NCT05687123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo a blood sample collection
Study NCT05687123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan
Study NCT05687123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given IV
Study NCT05687123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05687123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a SSR PET/CT scan
Study NCT06634862 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Soft Tissue Mobilization
Description: The soft tissue mobilisation technique has been investigated in other studies in terms of its effect on soft tissue and its role recovery. In this way, there is no comparison with other recovery interventions for post-exercise recovery applications.
Study NCT05371678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic motor control interventions
Description: Treatment duration will be 8 weeks, two sessions a week. Each session will take approximately 60 minutes. This intervention includes education, dietary advices, core stabilization exercises and pelvic floor muscle training with surface Electromyographic-Biofeedback. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Core stabilization exercises will be performed 2 days a week with a physiotherapist and the session will be approximately 50 minutes. Diaphragmatic breathing will be taught to children in breathing exercises. The pelvic floor muscles exercises will be do by surface Electromyographic-Biofeedback. The Electromyographic-Biofeedback teaches the child how to relax the external anal sphincters with visual and auditory feedback techniques.The child will learn to relax the pelvic floor muscles during defecation by monitoring the recorded electromyographic activity.
Study NCT05371678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Treatment duration will be 8 weeks. This intervention includes education, dietary advices and laxative therapy. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Laxative therapy will be adjusted at different doses according to the child's age and weight. Laxative therapy will be administered to children by a specialist doctor.
Study NCT06634862 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Percussive therapy
Description: Percussive therapy has been investigated in device research and athlete health. In this way, it has not been compared with other recovery interventions for post-exercise recovery applications.
Study NCT06636422 — intervention group
Intervention type: DRUG
Intervention: Motherwort injection
Description: Patients will be given motherwort injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
Study NCT05687123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study NCT06444347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biosynthetic Mesh
Description: The biosynthetic mesh group will undergo hiatal hernia repair with Phasix Mesh (Becton Dickinson, Franklin Lakes, NJ) reinforcement, secured with permanent suture.
Study NCT05475262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active white noise
Description: Active white noise of 57 dB - 60 dB from 10 pm to 6 am
Study NCT05318482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational group
Description: In addition to the activities of the usual rehabilitation program, the PT will perform a daily motivational session of 15 minutes in a 1 patient: 1 physiotherapist modality. On that occasion, the patient will report the number of steps performed the previous day; the physiotherapist will check and promote the increase of 10% in the number of steps for the next day. If the patient fails to achieve the goal, the PT will analyze the reasons with the patient, in order to facilitate the achievement of the goal. The PT will advise on the time and place to perform physical activity and the patients will receive a diary to record his/her progress (number of steps and heart rate, Borg Fatigue and Borg Dyspnea before and after an exercise task). The PT will record all these evaluations on an excel database.
Study NCT05318482 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Besides the activities of the usual rehabilitation program, the patients of this group will be provided by the PT only with the generic recommendations of daily exercise during the in-hospital stay
Study NCT05475262 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive white noise
Description: Sham comparator - white noise machine played at lower decibel level not expected to impact sound level changes
Study NCT05599321 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual Navigation System
Description: The Virtual Navigator guidance computer is interfaced to the bronchoscopy hardware to tap off the live bronchoscopy and EBUS video feeds. The standard OR medical team (technicians, clinical fellows, et al.) is on hand, and standard clinical facilities (e.g., fluoroscopy, CT/PET image viewer) are available. Our technical team is also present to record all procedural video and computer display information. It also operates the guidance computer during the guided procedure and offers any assistance in case of unanticipated issues. The participant's clinical bronchoscopy will be recorded by the radiology imaging management system.
Study NCT05272488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy and vagus nerve stimulation
Description: A neurodinamic intervention of vagus nerve through deep breaths involving diaphragm muscle and manual therapy techniques.
Study NCT05272488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Manual therapy techniques. Joint manipulation techniques for temporomandibular joints and Soft tissue techniques for the muscles
Study NCT05010408 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD) at different sweetness levels
Description: Beverage
Study NCT05010408 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD) at different sweetness levels
Description: Beverage
Study NCT06532591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin
Description: PD-1/CTLA-4 bispecific antibody，Cadonilimab 10mg/kg IV, q3w, paclitaxel 175mg/m2 or albumin-bound paclitaxel 260mg/m2 ivgtt d1, q3w carboplatin AUC 5 ivgtt d1, q3w
Study NCT06448247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPY001-001
Description: Experimental
Study NCT06448247 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05421923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR1375 capsules
Description: Ascending single and multiple doses of SR1375 orally
Study NCT05421923 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending single and multiple doses of Placebo orally
Study NCT06161610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LITT
Description: The patients in the intervention group will receive LITT, other treatments, including systematic therapy and radiology therapy, would be not restricted except the craniotomy of resection before tumor progression or emergency. The patient is supposed to receive LITT post-randomization within 7 days.
Study NCT06161610 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The patients in the control group will receive the best medical management under guidelines except LITT before tumor progression. Craniotomy will not be restricted,
Study NCT05281172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Change therapy (GSC)
Description: The GSC program follows a motivational cognitive-behavioral approach designed to minimize resistance in drug behavior changes, prevent relapse risk, and increase motivation to quit. The GSC consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
Study NCT05281172 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation program about healthy habits
Description: The psychoeducational program will include talks about healthy habits such as physical activity, relaxation, and sleep hygiene. This intervention consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
Study NCT06442891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure Therapy
Description: Self-administer relaxing acupressure
Study NCT06444347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hiatal Hernia Repair
Description: The non-mesh group will undergo hiatal hernia repair with permanent suture only.
Study NCT06444347 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hiatal Hernia Repair
Description: The non-mesh group will undergo hiatal hernia repair with permanent suture only.
Study NCT05659992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte
Description: 1. azacytidine (75 mg/m2/day, days 1 to 7).~2. cytarabine (75 mg/m2 bid, days 1 to 5).~3. aclamycin (10 mg/m2/day, day1,3,5).~4. Chidamide (30 mg/day , days 0,3).~5. venetoclax (100 mg day 1, 200 mg day 2, 400mg days 3 to 14 ).~6. granulocyte colony-stimulating factor (5ug/kg/day, day 0 until agranulocytosis recovery)
Study NCT05555758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adamgammadex Sodium
Description: Aom0319 will be administered intravenously with water for injection.
Study NCT05555758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: 0.9% Sodium Chloride will be administered intravenously.
Study NCT06553313 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Micro-Western Array
Description: The subjects first took the energy measurement of the pulse sphygmograph and Ryodoraku, rested for 20 minutes, and then repeated the measurements again. In order to comply with the acupuncture treatment course was 5 weeks in the previous study, we have two blood draw point. Each subject's blood was drawn for the first time, and then for the second time in 5 weeks later. Each subject drew 10ml of blood each time. The blood samples are analyzed by Micro-Western Array (MWA) and Enzyme-linked immunosorbent assay (ELISA) to obtain the serum protein content value of healthy individuals.
Study NCT06144697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986465
Description: Specified dose on specified days
Study NCT04723108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Destek V4 Virtual Reality Headset
Description: The DESTEK V4 is a smartphone VR headset made by DESTEK, a manufacturer based in the US. This mobile virtual reality headset is compatible with most iOS and Android smartphones, as long as their screen size is between 4.5 and 6.
Study NCT06144697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT06144697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: Specified dose on specified days
Study NCT06144697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Specified dose on specified days
Study NCT05416151 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Freeze-dried biotic
Description: 2 sticks of 3g consumed daily for 28 days
Study NCT05416151 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Maltodextrin
Description: 2 sticks of 3g consumed daily for 28 days
Study NCT06442891 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Acupressure Therapy
Description: Self-administer sham acupressure
Study NCT06442891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive access to acupressure mobile app
Study NCT06442891 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Internet-Based Intervention
Description: Receive access to acupressure mobile app
Study NCT06442891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study NCT06442891 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Interview
Description: Ancillary studies
Study NCT06442891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Receive an AcuWand
Study NCT06442891 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Receive an AcuWand
Study NCT06442891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06442891 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05749211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier granule
Description: Oral administration, 20 g once, 3 times a day, continued until progression or intolerance of toxicity
Study NCT06300632 — intervention group
Intervention type: OTHER
Intervention: geriatric locomotive syndrome
Description: Elderly individuals will be included in the study. Before each elderly person starts the study, they will be informed about the content of the study and they will read and sign the consent form stating that they participate in the study voluntarily. Socio-demographic data (age, body mass index, and family history, fall history, ) of all individuals participating in the study will be recorded.Within the scope of the evaluation, locomotive syndrome evaluation will be made through a survey. Fear of movement will be evaluated with the Tampa kinesiophobia scale, your physical activity level with the physical activity scale for the elderly, your physical performance with the short physical performance battery, your fatigue level with the fatigue severity scale, and your cognitive functions with the Montreal Cognitive Assessment Scale.
Study NCT05178654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]PF-07321332
Description: Single oral dose of 300 mg \[14C\]PF-07321332 containing approximately 100 µCi \[14C\]PF-07321332 coadministered with 100 mg ritonavir.
Study NCT05005078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST-057
Description: WST-057 topical solution
Study NCT05005078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: WST-057 Matching placebo
Study NCT06418750 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: dermo-cosmetic product
Description: For patients in the preventive group, treatment with hand serum, gloves/slippers and fortifying solution/dissolving oil will be started on the day of the first administration of Ac bispecific. In the curative group, treatment will begin on inclusion in the study and will be adapted to the lesions present on D0. Treatment will be readjusted on a weekly basis according to the lesions present at the time of the follow-up visit.
Study NCT06240728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPX887
Description: NPX887 will be administered by IV infusion every 3 weeks until documented disease progression or participant withdrawal for up to 2 years
Study NCT05069415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eyhance IOL
Description: Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target emmetropia OU.
Study NCT05069415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyhance IOL
Description: Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target emmetropia OU.
Study NCT05069415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eyhance IOL
Description: Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target mini monovision in the non-dominant eye.
Study NCT05069415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyhance IOL
Description: Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target mini monovision in the non-dominant eye.
Study NCT06286072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and message
Description: COPD general education content and fatigue-specific coping strategies. Messages sent to phones